TREA

79302549 - BILIX

Follow

Information

  • Trademark
  • 79302549
  • Serial Number
    79302549
  • Registration Number
    6835721
  • Filing Date
    November 11, 2020
    4 years ago
  • Registration Date
    September 06, 2022
    2 years ago
  • Transaction Date
    January 03, 2023
    2 years ago
  • Status Date
    September 06, 2022
    2 years ago
  • Published for Opposition Date
    June 21, 2022
    2 years ago
  • Location Date
    September 06, 2022
    2 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    LAM, HAI-LY HUYNH
  • Attorney Docket Number
    4897.0001
    Attorney Name
    James R Menker
    Law Office Assigned Location Code
    N10
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
BILIX
Case File Statements
  • GS0051: Pharmaceutical preparations for neurological disease; pharmaceutical preparations for inflammatory diseases; pharmaceutical preparations for ocular and intraocular surgery; pharmaceutical preparations for rare autoimmune diseases in the nature of autoimmune lymphoproliferative syndrome, lupus, and multiple sclerosis; pharmaceutical products for the treatment of rare autoimmune diseases and disorders; pharmaceutical products for the prevention and treatment of rare genetic diseases affecting red blood cells; medicated ointments for treating dermatological conditions; antibiotic ointments; mentholated ointment for medical use; anti-inflammatory ointments; chemical reagents for purposes of medical diagnosis; diagnostic preparations for diagnosing inflammatory diseases; diagnostic radiopharmaceutical preparations; pharmaceutical and biological preparations for use in diagnosis, namely, for use as ultrasound and x-ray contrast reagents; antibiotics; anti-inflammatory preparations; anti-cancer preparations; biological preparations for the treatment of cancer; cardiovascular pharmaceutical preparations; dermatological pharmaceutical products; diagnostic preparations for medical or veterinary purposes; genetic identity tests comprised of reagents for medical purposes; human vaccine preparations; medicines for dental purposes; medicines for intestinal disorders; ophthalmic preparations; pharmaceutical agents affecting digestive organs; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical agents affecting sensory organs; pharmaceutical preparations acting on the central nervous system; pharmaceutical agents for epidermis; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating skin disorders; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for treating respiratory diseases; pharmaceuticals for the treatment of erectile dysfunction; preparations for the treatment of asthma; tumor suppressing agents; vaccines; immunoassay reagents for medical use
  • GS0421: Pharmaceutical research services; drug discovery services; medical research; pharmaceutical product evaluation; scientific investigations for medical purposes; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; consulting on the testing, inspection and research of medical products for quality control purposes; providing information on the testing, inspection and research of medical products for quality control purposes; industrial research in the fields of medicine, health and pharmacology; engineering services in the medical technology field
Case File Event Statements
  • 1/3/2023 - 2 years ago
    42 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 12/9/2022 - 2 years ago
    41 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 12/9/2022 - 2 years ago
    40 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 12/6/2022 - 2 years ago
    39 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 9/6/2022 - 2 years ago
    38 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 9/6/2022 - 2 years ago
    37 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 7/11/2022 - 2 years ago
    36 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 7/5/2022 - 2 years ago
    35 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 6/22/2022 - 2 years ago
    34 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 6/22/2022 - 2 years ago
    33 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 6/21/2022 - 2 years ago
    32 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 6/21/2022 - 2 years ago
    31 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 6/8/2022 - 2 years ago
    30 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 6/8/2022 - 2 years ago
    29 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 6/1/2022 - 2 years ago
    28 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 5/13/2022 - 2 years ago
    27 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 4/28/2022 - 2 years ago
    26 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 4/28/2022 - 2 years ago
    25 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 4/28/2022 - 2 years ago
    24 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 4/28/2022 - 2 years ago
    23 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 3/31/2022 - 2 years ago
    22 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 3/31/2022 - 2 years ago
    21 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 3/31/2022 - 2 years ago
    20 - ASSIGNED TO LIE Type: ALIE
  • 3/29/2022 - 2 years ago
    19 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 3/29/2022 - 2 years ago
    18 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 3/29/2022 - 2 years ago
    17 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 3/29/2022 - 2 years ago
    16 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 10/29/2021 - 3 years ago
    15 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 10/29/2021 - 3 years ago
    14 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 10/29/2021 - 3 years ago
    13 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 9/30/2021 - 3 years ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 9/30/2021 - 3 years ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 9/30/2021 - 3 years ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 5/17/2021 - 3 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 4/26/2021 - 3 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 4/26/2021 - 3 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 4/23/2021 - 3 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 4/22/2021 - 3 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 4/21/2021 - 3 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 1/26/2021 - 4 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 1/22/2021 - 4 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 1/21/2021 - 4 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR